416 related articles for article (PubMed ID: 30693099)
1. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.
Tan MH; Iyengar R; Mizokami-Stout K; Yentz S; MacEachern MP; Shen LY; Redman B; Gianchandani R
Clin Diabetes Endocrinol; 2019; 5():1. PubMed ID: 30693099
[TBL] [Abstract][Full Text] [Related]
2. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
3. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS
Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
[TBL] [Abstract][Full Text] [Related]
4. Endocrinopathies Associated With Immune Checkpoint Inhibitor Use.
Kotwal A; Kennedy R; Kikani N; Thosani S; Goldner W; Shariff A
Endocr Pract; 2024 Jun; 30(6):584-591. PubMed ID: 38554775
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
6. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
8. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
9. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
Atkinson M; Lansdown AJ
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
[TBL] [Abstract][Full Text] [Related]
10. The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.
Mytareli C; Ziogas DC; Karampela A; Papalexis P; Siampanopoulou V; Lafioniatis A; Benopoulou O; Gogas H; Angelousi A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046677
[TBL] [Abstract][Full Text] [Related]
11. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
12. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies.
Chen H; Zhang L; Zhao L; Li X
BMC Endocr Disord; 2023 Jul; 23(1):139. PubMed ID: 37415148
[TBL] [Abstract][Full Text] [Related]
13. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
14. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors.
Fujita Y; Kamitani F; Yamamoto M; Fukuoka H; Hirota Y; Nishiyama N; Goda N; Okada Y; Inaba Y; Nakajima H; Kurematsu Y; Kanie K; Shichi H; Urai S; Suzuki M; Yamamoto N; Bando H; Iguchi G; Suto H; Funakoshi Y; Kiyota N; Takahashi Y; Ogawa W
J Endocr Soc; 2023 Jan; 7(3):bvad002. PubMed ID: 36694808
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
18. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
19. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy.
Chiloiro S; Bianchi A; Giampietro A; Milardi D; De Marinis L; Pontecorvi A
Trends Endocrinol Metab; 2022 Feb; 33(2):87-104. PubMed ID: 34895977
[TBL] [Abstract][Full Text] [Related]
20. It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia.
Bischoff J; Fries C; Heer A; Hoffmann F; Meyer C; Landsberg J; Fenske WK
J Endocr Soc; 2022 May; 6(5):bvac036. PubMed ID: 35356006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
